Today's Date: September 26, 2023
International Green Industry Hall of Fame to Name Three Inductees in 2023 Virtual Ceremony   •   Pivot Bio Expands Leadership Team to Accelerate Momentum   •   Atlanta High School Entrepreneurs Benz and Popo Are Empowering Teens Globally During International Strategic Thinking Month   •   Strategic Education, Inc. Schedules Third Quarter 2023 Results Conference Call and Provides Registration Details for 2023 Invest   •   ERI Featured in New York City’s “Follow Your Waste” Interactive Educational Platform   •   Six Weeks After Deployment, Brandenburg Telecom Grows Bark Offering To Help Protect 3X More Kentucky Families From Social Media   •   New research explores why more people don't tap into home equity to help fund retirement   •   Granite Wins Six Safety and Environmental Awards From NSSGA   •   Newly formed Senior Living Transformation Company partners with Omega Healthcare Investors (NYSE: OHI) to launch the Senior Livi   •   Statement - Canadian overseas memorials granted World Heritage status   •   Soluna Project Dorothy 1 Reaches Full Capacity of 50 MW, Company hits 2.6 EH/s Hashrate Milestone   •   Wondershare FamiSafe 7.0 safeguarding Children with AI   •   NextUp Launches "You Are NextUp" Campaign Celebrating Women in Business   •   US Marine Corps Veteran Partners with Local Nonprofit to Combat Those with Housing Insecurity with New Junk Removal Business   •   AlphaGraphics Make It Happen Event Makeover Contest Announces Final Winners with a Combined Value of $80,000   •   Ascent Protein Partners with Susan G. Komen® with Custom Pink Packaging   •   American BioCarbon Achieves Commercial Pre-certification with   •   Kids Help Phone (KHP), Elevate and MaRS announce a $2 Million innovation challenge, aimed at reshaping the youth mental health e   •   Lightbridge Academy Announces First Franchise Signing in Colorado, Bringing High-Quality Early Child Care to the Rocky Mountain   •   Jessica Biella Named Recipient of 2023 Women in Supply Chain Award
Bookmark and Share

ST Pharm breaks ground on 2nd State-of-the-Art Oligonucleotide Facility

ST Pharm breaks ground on 2nd State-of-the-Art Oligonucleotide Facility

PR Newswire

SEOUL, South Korea, Sept. 18, 2023 /PRNewswire/ -- ST Pharm successfully marked the completion of its groundbreaking ceremony, signaling a significant step forward in expanding its oligonucleotide manufacturing capacity and capabilities.

The current expansion is in response to the growing demand for oligonucleotide therapeutics, including ASO, siRNA, and CRISPR, and it is not only to increase the capacity from 6.4 mol to 14 mol, but also to enhance overall capabilities.

To diversify its operational scope, the new facility will be designed to accommodate different scales of production. Initially, it will introduce three new production lines, with capacities of 1.8 mol (large scale), 400 mmol (mid scale), and 100 mmol (small scale), and the facility has flexibility to add two more lines for future growth.

With a total investment of $110 million USD, the construction of the new oligonucleotide facility at ST Pharm Banwol Campus planned for completion in 2025 will cover approximately 3,300 squares meters (10,900㎡), standing at a height of 60 meters across 7 floors.

The state-of-the-art facility will harness automation and digitization to streamline operations and leverage know-how that is already available for enhanced productivity, robustness, and agility resulting in reduced labor cost and improved overall cost-efficiency.  

Furthermore, ST Pharm is dedicated to reducing its carbon footprint and advancing sustainability. The new facility will implement waste recycling, water-saving process, and introduce the new technologies that extend lifespan of filters, and energy-efficient technologies.

Research & Markets predicts substantial growth in the oligonucleotide therapeutics market, with a projected increase from $7.70 billion USD in 2021 to $16.36 billion USD in 2030, reflecting a robust CAGR of 11.8% (Source: Data Bridge 2022, Oligonucleotide Synthesis Market Research Report). Oligonucleotides were primarily used for rare disease treatments, but with the expansion of their applications to chronic disease and beyond it is experiencing surging global demand. Notable examples include Novartis' Inclisiran for cholesterol treatment and Pelacarsen for cardiovascular disease. 

About ST Pharm

ST Pharm is a technology-driven CDMO, specializing in the development, manufacturing, and commercialization of oligonucleotides, mRNA, and small molecule APIs. ST Pharm has firmly established itself as a leading global provider of oligonucleotide APIs. Leveraging its profound know-how in development and manufacturing of nucleotides and oligonucleotides, ST Pharm expanded its business scope to mRNA CDMO, utilizing its own mRNA platform technology. To learn more about ST Pharm, visit or follow ST Pharm on LinkedIn 

Cision View original content:

SOURCE ST Pharm Co., Ltd.

Back to top
| Back to home page

White House Live Stream
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News